TrialCancer medicine2020

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

Anja Welt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.